RxDoctor Payments Data

Noy Ashkenazy, MD

Retina Specialist · Dallas, TXNPI 1083009260

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,944 of the $2,794 with a category attached, or 69.6%. 8 manufacturers reported payments, led by Dutch Ophthalmic, USA at 28.0% of the total. Reporting peaked in 2022 at $963 and has fallen 83.9% since, to $155 in 2025. That places this record below the midpoint for retina specialist clinicians in TX, where the typical reported total is $2,568.

$2,794in general payments, 2019–2025

Across 19 payments — averaging $147.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dutch Ophthalmic, USA$781
  • Alcon$759
  • Alimera Sciences, Inc.$531
  • Genentech USA, Inc.$366
  • Eyepoint US, Inc.$220
  • Novartis$99
  • plus $37 from 2 others

What the payments were for

  • Consulting fees$50018%
  • Speaking & faculty fees$35013%
  • Food & beverage$1,94470%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,794 in reported general payments places this provider in the 50th percentile of 108 retina specialist providers in Texas.

See all retina specialist providers in Texas

Medicare billing

Part B allowed, 2024
$124,384
Medicare patients
204
Services billed
1,349

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab14$112,582
IlevroNepafenac25$9,527
Difluprednate28$3,137
Prednisolone Acetate64$2,701
ValacyclovirValacyclovir Hcl14$1,225
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat46$729
Atropine Sulfate16$692
Brimonidine Tartrate35$619
Ketorolac Tromethamine11$454
Latanoprost47$182
Prednisone28$161
ErythromycinErythromycin Base12$143
Timolol Maleate19$66
MethotrexateMethotrexate Sodium13$10

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisIlevro$99$9,52725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 108 retina specialist providers in Texas.

Other retina specialist in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →